Artelo Biosciences, Inc.
ARTL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621221
No open-market purchases or sales by Artelo Biosciences, Inc. insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $132.0K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Artelo Biosciences, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 9 | 9 | 0 |
| Shares | 16.6K | 33.0K | +16.5K (+99.2%) |
| Value | $220.1K | $151.7K | −$68.5K (−31.1%) |
New holders (3)
Institutions that held Artelo Biosciences, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| DRW Securities, LLC | 17,185 | $78.9K | 0.00% |
| Vanguard Group Inc | 14,028 | $64.4K | 0.00% |
| Rothschild Investment LLC | 2 | $9 | 0.00% |
Sold out (3)
Institutions that held Artelo Biosciences, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Geode Capital Management, LLC | 16,032 | $212.7K |
| Tower Research Capital LLC (TRC) | 447 | $5.93K |
| Danske Bank A/S | 1 | $13 |